[
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
[og_img]
https://www.investing.com/news/press-releases/revolution-medicines-presents-initial-data-from-zoldonrasib-rmc9805-study-in-patients-with-kras-g12d-mutant-nonsmall-cell-lung-cancer-at-the-2025-aacr-annual-meeting-93CH-4006004
Investing.com
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
Related articles
